GrowthBusiness.co.uk: Your gateway to entrepreneurial success

Simon Daniel

A more stable currency

In the past 12 months, the pound has plummeted against the dollar and the euro....

RSS

Drug developer in lively debut

Article Date: Mar 12 2007

Nervous disorders drug developer Neuropharm nudged up by 14.5p to 141.5p on its AIM debut last week, following a £20 million placing at 127p.

Tom Hunter’s West Coast Capital is among the backers of the twelve year old business, which has received fast-track development status from the US Food & Drugs Administration to use Prozac ingredient fluoxetine to treat autistic spectrum disorder.

Broker and adviser Investec Investment Banking handled the placing for Neuropharm, steered by chief executive officer Robert Mansfield, who commented that the AIM admission and associated fundraising mark ‘important steps in the delivery of our strategy both to bring to market a much-needed treatment for autistic spectrum disorder and to advance the other products in our pipeline’.

Comments

There are currently no comments on this article

Research

Institutional Investors in AIM 2008

Growth Company Investor presents this brand new research of institutional activity on AIM.

VCT Special Report 2008

A comprehensive report on VCTs and over £1 billion in investment trusts just waiting to be invested in fast growth ventures.

Cash Shells 2008

A comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape.

M&A Awards 2009

18th February, London Hilton, Park Lane, London

M&A Expanding internationally

27th November, Sofitel London St James

Business North West

19th November, Manchester Central formerly G-MEX

Private shareholdings halve in 18 months

The value of private shareholdings in the UK stock market fell to £138 billion by September as a result of net selling and falling valuations.

Rathbone starts offshore sell-off

London-based wealth management specialist Rathbone Brothers has sold its trust operations in Jersey to its management team.

‘Severe illiquidity’ hurts AIM VCT

Pennine AIM VCT has announced a year-on-year decline of more than one-third in its net asset value per share, from 70.7p to 44.1p, as Chairman Hugh Gillespie says the fund’s management is constrained by the ‘severe illiquidity of most AIM stocks, along with the restrictions imposed by the VCT regulations’.

Poll

Have your vote on current issues

White Papers

Better Roads

Serves the information needs of governments and construction contractors involved in Federal, State, County, City and Township highway, road and bridge construction, winter maintenance, roadside and vegetation management and other highway-related projects.

GrowthBusiness.co.uk: Your gateway to entrepreneurial success

Nick Britton

Simon Daniel

Michael Jackson

Chris Ingram

Sign up / Login

Edit profile / Log out

Drug developer in lively debut

Comments

Related articles

Poll

Site map

GrowthBusiness Highlights